Depression
Conditions
Brief summary
No change in the rivastigmine group on cognitive and memory related measures (compared to an effect in the placebo group): significant interaction term between placebo and rivastigmine AND non-significant comparison on cognition and memory measures in the rivastigmine group between the timepoints (versus significant difference in the placebo group): at p <0.05, Classification algorithm for ECT response: accurate and statistically significant at p<0.05, Classification algorithm for side effects: accurate and statistically significant at p<0.05
Detailed description
To investigate quality of life related measures after rivastigmine addition: significant for the different measures at p<0.05, To investigate whether free speech is predictive of the antidepressant effects: classification (significant at p<0.05) AND significant (non)linear modelling at p<0.05, To investigate whether EEG could predict cognitive impairment: accurate and statistically significant at p<0.05, To investigate how network related measures change during an ECT course: statistically significant change between timepoints (p<0.05), To investigate how blood and DNA methylation change during ECT (or are predictive): p<0.05, To develop a comprehensive prediction method based on the available parameters: statistically significant change between timepoints (p<0.05), To investigate subjective measures of (anticipation) of response and side effects: p < 0.05
Interventions
DRUGRIVASTIGMINE
DRUGRivastigmin adhesive plaster 9.5 mg placebo containing 0 mg of rivastigmin
DRUGRivastigmin adhesive plaster 4.6 mg placebo containing 0 mg of rivastigmin
Sponsors
Universitair Medisch Centrum Groningen
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| No change in the rivastigmine group on cognitive and memory related measures (compared to an effect in the placebo group): significant interaction term between placebo and rivastigmine AND non-significant comparison on cognition and memory measures in the rivastigmine group between the timepoints (versus significant difference in the placebo group): at p <0.05, Classification algorithm for ECT response: accurate and statistically significant at p<0.05, Classification algorithm for side effects: accurate and statistically significant at p<0.05 | — |
Secondary
| Measure | Time frame |
|---|---|
| To investigate quality of life related measures after rivastigmine addition: significant for the different measures at p<0.05, To investigate whether free speech is predictive of the antidepressant effects: classification (significant at p<0.05) AND significant (non)linear modelling at p<0.05, To investigate whether EEG could predict cognitive impairment: accurate and statistically significant at p<0.05, To investigate how network related measures change during an ECT course: statistically significant change between timepoints (p<0.05), To investigate how blood and DNA methylation change during ECT (or are predictive): p<0.05, To develop a comprehensive prediction method based on the available parameters: statistically significant change between timepoints (p<0.05), To investigate subjective measures of (anticipation) of response and side effects: p < 0.05 | — |
Countries
Netherlands
Outcome results
None listed